表1　ワクチン（X-179A）による抗体産生誘導能（初回免疫：d28、追加免疫：d42）

ワクチン特異的抗体価 (ug/ml)

全粒子ワクチン		スプリットワクチン	
d28	d42	d28	d42
1.99	5.60	1.17	31.92
1.97	7.60	1.22	13.43
			33.93

HI抗体価

全粒子ワクチン		スプリットワクチン	
d28	d42	d28	d42
640	1280	80	2560
320	1280	40	5120
			1280

中和抗体価

全粒子ワクチン		スプリットワクチン	
d28	d42	d28	d42
640	3200	160	3200
640	3200	80	6400
			1600

表2　ワクチン（PR8）による抗体産生誘導能（初回免疫：d28、追加免疫：d42）

ワクチン特異的抗体価 (ug/ml)

全粒子ワクチン		スプリットワクチン	
d28	d42	d28	d42
0.43	10.44	0.077	27.49
0.27	0.93	0.056	49.09
0.12	0.21	0.040	6.49

HI抗体価

全粒子ワクチン		スプリットワクチン	
d28	d42	d28	d42
40	640	20	640
80	160	20	2560
80	320	40	640

中和抗体価

全粒子ワクチン		スプリットワクチン	
d28	d42	d28	d42
160	3200	40	3200
80	800	20	6400
80	800	10	800

研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kazuo Ohnishi, Yoshimasa Takahashi, Naoko Kono, Noriko Nakajima, Fuminori Mizukoshi, Shuhei Misawa, Takuya Yamamoto, Yu-ya Mitsuki, Shu-ichi Fu, Nakami Hirayama, Masamichi Ohshima, Manabu Ato, Tsutomu Kageyama, Takato Odagiri, Masato Tashiro, Kazuo Kobayashi, Shigeyuki Itamura and Yasuko Tsunetsugu-Yokota	Immunological detection of H5N1 influenza viruses by newly established monoclonal antibodies.	Jpn. J. Infect. Dis.	65	19-27	2012
Ruth Harvey, Michelle Hamill, James S Robertson, Philip D Minor, Galina M Vodeiko, Jerry P Weir, Hitoshi Takahashi, Yuichi Harada, Shigeyuki Itamura, Pearl Bamford, Tania Dalla Pozza, and Othmar G Engelhardt.	Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.	Biologicals	40	96–99	2012

Original Article

Newly Established Monoclonal Antibodies for Immunological Detection of H5N1 Influenza Virus

Kazuo Ohnishi[1], Yoshimasa Takahashi[1], Naoko Kono[2], Noriko Nakajima[3], Fuminori Mizukoshi[1], Shuhei Misawa[4], Takuya Yamamoto[1], Yu-ya Mitsuki[1], Shu-ichi Fu[1], Nakami Hirayama[1], Masamichi Ohshima[1], Manabu Ato[1], Tsutomu Kageyama[2], Takato Odagiri[2], Masato Tashiro[2], Kazuo Kobayashi[1], Shigeyuki Itamura[2], and Yasuko Tsunetsugu-Yokota[1]*

[1]Department of Immunology, [2]Influenza Virus Research Center, and
[3]Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640; and
[4]Tsuruga Institute of Biotechnology, Toyobo, Co., Ltd., Fukui 914-8550, Japan

SUMMARY: The H5N1 subtype of the highly pathogenic (HP) avian influenza virus has been recognized for its ability to cause serious pandemics among humans. In the present study, new monoclonal antibodies (mAbs) against viral proteins were established for the immunological detection of H5N1 influenza virus for research and diagnostic purposes. B-cell hybridomas were generated from mice that had been hyperimmunized with purified A/Vietnam/1194/2004 (NIBRG-14) virion that had been inactivated by UV-irradiation or formaldehyde. After screening over 4,000 hybridomas, eight H5N1-specific clones were selected. Six were specific for hemagglutinin (HA) and had in vitro neutralization activity. Of these, four were able to broadly detect all tested clades of the H5N1 strains. Five HA-specific mAbs detected denatured HA epitope(s) in Western blot analysis, and two detected HP influenza virus by immunofluorescence and immunohistochemistry. A highly sensitive antigen-capture sandwich ELISA system was established by combining mAbs with different specificities. In conclusion, these mAbs may be useful for rapid and specific diagnosis of H5N1 influenza. Therapeutically, they may have a role in antibody-based treatment of the disease.

INTRODUCTION

The highly pathogenic (HP) H5N1 avian influenza virus caused the first outbreak in humans in Hong Kong in 1997. This outbreak resulted in the infection of 18 people and resulted in six deaths (1,2). Thereafter, it was determined that H5N1 avian influenza virus was continuously circulated among geese in Southeastern China. Eventually, it spread to other Southeast Asian countries, where it severely damaged poultry farms (3,4). Subsequent H5N1 outbreaks in humans occurred in China and Vietnam in 2003 and in Indonesia in 2005. The most recent endemic has occurred in Egypt. According to a World Health Organization report, the H5N1 avian influenza virus had infected 565 people and resulted in 331 deaths by August 19, 2011 (5). Therefore, although sporadic, this fatal human infection is persistent and has the potential to cause serious future pandemics.

In humans, infection with HP H5N1 avian influenza virus causes high fever, coughing, shortness of breath, and radiological findings of pneumonia (6–8). In severe cases, rapidly progressive bilateral pneumonia develops, causing respiratory failure and may be responsible for the high mortality associated with this virus. de Jong et al. analyzed human cases of H5N1 infection and found that a high viral load and the resulting intense inflammatory response caused severe symptoms; furthermore, viral RNA was frequently detected in the rectum, blood, and nasopharynx (9). Thus, it is essential to detect HP influenza virus infection early and rapidly in order to provide early interventions that protect patients from devastating respiratory failure that arises from a high viral load. Additionally, early viral detection would facilitate rapid identification of infected patients and prevent unregulated contact with other people.

The present diagnostic standard for HP H5N1 influenza is the presence of the neutralization antibody. However, it takes more than 1 week for H5N1-specific antibodies to develop, and a well-equipped biosafety level 3 (BSL3) laboratory is required for the virus neutralization assay. A simpler method is the hemagglutination-inhibition assay using horse erythrocyte. This method has been widely performed on paired acute and convalescent sera from patients with HP H5N1 influenza virus infections. Although this method has acceptable sensitivity, its specificity has been questioned (7).

Isolating the virus from patient samples is the gold standard for diagnosing an infection; however, this is not always possible. For example, the method of sample preparation and preservation strongly influence the ability to isolate the virus. Moreover, a BSL3 laboratory is essential. At present, the most sensitive and rapid method for initial diagnosis of H5N1 virus infections is by conventional or real-time reverse-transcriptase polymerase chain reaction (RT-PCR). However, this proce-

*Corresponding author: Mailing address: Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan. Tel: +81-3-5285-1111, Fax: +81-5285-1150, E-mail: yyokota@nih.go.jp

dure requires expertise in molecular virology and expensive equipment and reagents. Moreover, because of its high sequence specificity, this approach could fail to identify mutant influenza viruses that continually evolve due to a high mutation rate (8).

For screening suspected H5N1 influenza virus in the field, the ideal approach would be to employ an immunology-based technique that detects viral antigens. Such a method is simple and rapid. However, its sensitivity and specificity depend highly on the antibodies used. Thus, an immunological assay that uses appropriate specific antibodies against H5N1 in combination with specific antibodies against other subtypes of influenza virus or viruses that cause febrile diseases would be useful for screening in areas with endemic influenza-like illness. While there are several rapid influenza virus diagnostic systems available for seasonal influenza (10), few exist for H5N1 influenza. Therefore, we have developed a simple and rapid diagnostic system with high sensitivity and specificity for H5N1 influenza virus.

Influenza virus belongs to the family *Orthomyxoviridae*; its genome consists of a negative-sense, single-stranded RNA with eight segments, each encoding structural and non-structural proteins (11). Influenza A viruses are classified into several subtypes based on the hemagglutinin (HA) and neuraminidase (NA) serotypes. In total, there are 16 HA and 9 NA serotypes. The H5N1 viruses are divided into clades 1 and 2 based on their HA genotypes. Clade 2 has been further subdivided into five sub-clades (12). Clade 1 viruses were predominant in Vietnam, Thailand, and Cambodia in the early phase of the 2004–2005 outbreak, whereas clade 2.1 viruses were endemic in Indonesia at that time (8). These two viruses are the major prototypes for the preparation of prepandemic H5N1 vaccines. We used inactivated purified clade 1 virion [A/Vietnam/1194/2004 (NIBRG-14)] as an immunizing antigen to establish mouse monoclonal antibodies (mAbs) specific for H5N1 influenza virus. Characterization of these mAbs revealed that they could detect H5N1 viruses when used in an immunofluorescence staining assay (IFA), Western blotting analysis, immunohistochemistry, and antigen-capture sandwich ELISA. In addition, the mAbs had significant in vitro neutralization activity against H5N1 viruses, and some broadly detected both clade 1 and 2 viruses.

MATERIALS AND METHODS

Viruses and cell culture: The NIBRG-14 (H5N1) virus, which possesses modified HA and NA genes derived from the A/Vietnam/1194/2004 strain on the backbone of six internal genes of A/Puerto Rico/8/34 (PR8), was provided by the National Institute for Biological Standards and Controls (NIBSC; Potters Bar, UK). A/Indonesia/05/2005 (Indo5/PR-8-RG2), A/Turkey/1/2005 (NIBRG-23), A/Anhui/01/2005 (Anhui01/PR8-RG5) were also obtained from NIBSC. All non-H5N1 strains were obtained from a stockpile of seed vaccines of the Influenza Virus Research Center of the National Institute of Infectious Diseases. The live virus was manipulated in a BSL2 laboratory. To produce and purify the virion, the NIBRG-14 and PR8 viruses were propagated in the allantoic cavity of 10-day-old

embryonated hens' eggs and purified through a 10–50% discontinuous sucrose gradient by ultracentrifugation (13). The viruses were then resuspended in phosphate-buffered saline (PBS) and inactivated by ultraviolet (UV) irradiation or by treatment with 0.05% formalin at 4°C for 2 weeks. These preparations were served as the inactivated H5N1 virus fraction. These conditions have been previously shown to completely inactivate H5N1 viruses.

Production of mAbs: Nine-week-old female BALB/c mice (Japan SLC, Shizuoka, Japan) were immunized subcutaneously with 20 μg of UV- or formaldehyde-inactivated NIBRG-14 (H5N1) virus using Freund's Complete Adjuvant (Sigma, St. Louis, Mo., USA). Two weeks later, the mice were boosted with a subcutaneous injection of 5 μg of the inactivated virus emulsified with Freund's Incomplete Adjuvant (Sigma). Three days after the boost, sera from the mice were tested by ELISA to determine the antibody titer against the NIBRG-14 virus. The three mice with the highest antibody titers were given an additional boost 14 days after the first boost by intravenous injection of 5 μg of the inactivated virus. Three days later, the spleens of these three mice were excised, and the spleen cells were fused with Sp2/O-Ag14 myeloma cells using the polyethylene glycol method of Kozbor and Roder (14). The fused cells were cultured on twenty 96-well plates and selected with hypoxiantine-aminopterin-thymidine (HAT) medium. The first screening was conducted by ELISA using formalin-inactivated purified NIBRG-14 (H5N1) and PR-8 (H1N1) virions, which were lysed with 1% Triton X100. The lysates (1 mg/ml) were diluted 2,000-fold with ELISA-coating buffer (50 mM sodium bicarbonate, pH 9.6), and the ELISA plates (Dynatech, Chantily, Va., USA) were coated at 4°C overnight. After blocking with 1% ovalbumin in PBS-Tween (10 mM phosphate buffer, 140 mM NaCl, 0.05% Tween 20, pH 7.5) for 1 h, the culture supernatants of the HAT-selected hybridomas were added and incubated for 1 h. After washing with PBS-Tween, the bound antibodies were detected using alkaline phosphatase-conjugated anti-mouse IgG (1:2,000; Zymed, South San Francisco, Calif., USA) and *p*-nitrophenyl phosphate, which served as a substrate. In this first screening, hybridomas that reacted to the H5N1 virus (NIBRG-14) but not to the H1N1 virus (PR-8) were selected.

Baculoviral expression of recombinant HA and NA: Recombinant HA (rHA) and NA (rNA) proteins were produced as previously described (13). Briefly, the HA- and NA-coding genes of NIBRG-14 were amplified by PCR to attach a 6x-His tag to the C terminus of HA and to the N terminus of NA. The amplified DNAs were then cloned into pBacPAK8 (Clontech, Mountain View, Calif., USA) and transfected into Sf-21 (*Spodoptera frugiperda*) insect cells. Recombinant baculoviruses containing the rHA and rNA genes were isolated were used to infect Sf-21 cells. The recombinant proteins tagged with 6x-His were purified with TALON columns (Clontech) according to the manufacturer's protocol.

Neutralization assay: For the neutralization assay, 100 TCID$_{50}$ of H5N1 virus, a standard tissue culture infectious dose for such assays, was incubated for 30 min at 37°C in the presence or absence of the purified mAbs, which had been serially diluted twofold. The viruses

were then added to MDCK cell cultures that had been grown to confluence in a 96-well microtiter plate. The virus strains used were A/Vietnam/1194/2004 (NIBRG-14) (H5N1) (clade 1), A/Indonesia/05/2005 (Ind05/PR8-RG2) (H5N1) (clade 2.1), A/Turkey/1/2005 (NIBRG-23) (H5N1) (clade 2.2), and A/Anhui/01/2005 (Anhui01/PR8-RG5) (H5N1) (clade 2.3). After 3–5 days, the cells were fixed with 10% formaldehyde and stained with crystal violet to visualize the cytopathic effects induced by the virus (15). Neutralization antibody titers were expressed as the minimum concentration of purified immunoglobulin that inhibited a cytopathic effect.

Western blot analysis: UV-inactivated purified H5N1 virus (0.5 μg/lane) was loaded on SDS-PAGE gels under reducing conditions. The proteins were then transferred to a PVDF membrane (Genetics, Tokyo, Japan). After blocking with BlockAce reagent (Snow Brand Milk Products Co., Tokyo, Japan), the membranes were detected with the mAbs or diluted sera (1:1,000) that had been obtained from mice immunized with UV-irradiated H5N1 virus. After washing, the membrane was reacted with the peroxidase-conjugated F(ab')$_2$ fragment of anti-mouse IgG (H + L) (1:20,000; Jackson ImmunoResearch, West Grove, Pa., USA), and the bands were visualized on X-ray film (Kodak, Rochester, N.Y., USA) with chemiluminescent reagents (Amersham Biosciences, Piscataway, N.J., USA).

Purification and biotinylation of mAbs: Hybridomas were grown in Hybridoma-SFM medium (Invitrogen, Carlsbad, Calif., USA) supplemented with recombinant IL-6, penicillin (100 U/mL), and streptomycin (100 μg/mL) (16). The culture supernatants were harvested, and 1/100 volume of 1 M Tris-HCl (pH 7.4) and 1/500 volume of 10% NaN$_3$ were applied directly on a Protein G-Sepharose 6B column (Amersham Biosciences). The column was washed with PBS and eluted with glycine/HCl (pH 2.8). After measuring the OD$_{280}$ of the fractions, the protein-containing fractions were pooled, and an equal volume of saturated (NH$_4$)$_2$SO$_4$ was added. The precipitated proteins were dissolved in PBS, dialyzed against PBS, and stored at −20°C. The purified antibodies were biotinylated with sulfo-NHS-LC-biotin (Pierce, Rockford, Ill., USA) according to the manufacturer's protocol.

Antigen-capture ELISA: The purified antigen-capturing mAb was immobilized on a microplate (Immulon 2; Dynatech) by incubating 4 μg/mL of the mAb in 50 mM sodium bicarbonate buffer (pH 8.6) at 4°C overnight. The microplate was blocked with 1% BSA, washed with PBS-Tween, and reacted with serial dilutions of UV-inactivated purified H5N1 virus for 1 h at room temperature. After washing with PBS-Tween, biotinylated probing mAb (0.1 μg/mL) was added to the wells for 1 h at room temperature. After washing, horseradish peroxidase (HRP)-labeled streptavidin (Zymed) was added to the wells for 1 h at room temperature. After washing, 0.4 mg/mL o-phenylenediamine (OPD Sigma P-8412) in OPD Buffer (0.05 M citrate-phosphate buffer pH 5.0, 0.04% H$_2$O$_2$) or TMB(+) substrate (DAKO, Kyoto, Japan) was added. The reaction was stopped by adding 2N H$_2$SO$_4$, and the OD$_{490}$ or OD$_{450}$ was measured using a multi-well plate reader (Flow Laboratories Inc., Inglewood, Calif., USA).

Immunohistochemistry: Lung tissues were harvested from mice infected with A/Vietnam/1194/2004 (NIBRG-14) or A/HongKong/483/97 (HK483). In addition, autopsied lung tissues of patients infected with influenza virus (H1N1 or 2009 H1N1pdm) were used. Formaldehyde- or formalin-fixed paraffin-embedded lung tissue sections were deparaffinized with xylene and graded ethanol and then autoclaved in 0.1 M citrate-buffer (pH 6.0) at 121°C for 10 min to retrieve the antigens. Endogenous peroxidase was inactivated with 0.3% hydrogen peroxide for 30 min at room temperature. After blocking with M.O.M. blocking reagent (Vector laboratories, Burlingame, Calif., USA) or 5% goat serum, the sections were incubated with each of the mouse mAbs or rabbit polyclonal antibody against type A influenza nucleoprotein at 4°C overnight. After washing off the excess antibodies, the sections were incubated with HRP-labeled anti-mouse IgG followed by tyramide signal amplification system (Biotin-free catalyzed amplification system, CSAII; DAKO) or biotinylated anti-rabbit IgG followed by streptavidin/HRP (LSAB kit; DAKO). The labeled peroxidase activity was detected using diaminobenzidine (DAB; Dojin, Kumamoto, Japan) in 0.015% hydrogen peroxide/0.05 M Tris-HCl (pH 7.6). The sections were counterstained with hematoxylin.

RESULTS

Generation of H5N1-specific mAbs: To establish hybridomas that secrete mAbs specific for the H5N1 virus, BALB/c mice were immunized with the whole virion fraction of purified A/Vietnam/1194/2004 (NIBRG-14) virus. The virus had been inactivated by conventional formaldehyde-fixation or by UV-irradiation to avoid possible changes in antigenicity caused by aldehyde fixation. A standard immunization protocol was used, where mice were boosted twice at 2-week intervals with antigen emulsified first in Freund's Complete Adjuvant and then in Freund's Incomplete Adjuvant. Three days after the final boost, a cell suspension was prepared from the spleens of three immunized mice and fused with SP-2/O myeloma using a polyethylene-glycol method. The fused cells were then selected with HAT (14). Hybridoma screening yielded eight hybridoma clones that reacted to NIBRG-14 lysate but not PR-8 lysate in ELISA (Table 1). Of these clones, seven were from mice immunized with UV-inactivated virion, and one was from mice immunized with formaldehyde-inactivated virion. Six clones (Niid_H5A, Niid_H5B, Niid_H5C, Niid_H5D, Niid_H5E, and Niid_H5F) reacted to rHA protein from a H5N1 virus (recHA_H5N1), while one clone (Niid_N1A) reacted to rNA protein from a H5N1 virus (recNA_H5N1). The remaining clone (Niid_150KA) did not react to either recHA_H5N1 or recNA_H5N1 by ELISA but did react to a 150-kDa molecule on Western blot analysis (described below). Interestingly, seven of the eight clones were from the mice immunized with UV-inactivated virus. The eight hybridomas were successfully cloned by a repeated limiting-dilution method and adapted to a serum-free hybridoma culture medium. The purified antibodies from each clone were biotinylated and used for further experiments.

Table 1. Summary of the eight H5N1-specific mAbs generated in this study

Clone name	Old name	Ig-subclass	ELISA				Western blot	IFA	Histology	Neutralization (μg/mL)	Hemagglutination inhibition
			H5N1_ NIBRG-14	H1N1_ PR-8	recHA_ H5N1	recNA_ H5N1					
Niid_H5A[1)	YH-1A1	IgG2a	+++	−	+	−	57 kDa	++		1.5 (Clade-dep)	−
Niid_H5B[1)	YH-2F11	IgG2a	+++	−	+++	−	57 kDa			25	+
Niid_H5C[1)	OM-A	IgG2a	+++	−	++	−	57 kDa		+(mo/hu)	12	
Niid_H5D[1)	OM-B	IgG2a	+++	−	++	−	57 kDa		+(mo)	12	
Niid_H5E[1)	OM-C	IgG2a	+++	−	++	−	57 kDa			12 (Clade-dep)	
Niid_H5F	AY-2C2	IgG1	+++	−	++	−	ND	++		6	−
Niid_N1A[1)	YH-2D3	IgG2a	+++	−	−	+	ND	++			
Niid_150KA[1)	OM-D	IgG1	+++	−	−	−	150 kDa	++			−

[1): Clones derived from mice immunized with UV-inactivated virus. The remaining clone is derived from a mouse immunized with formaldehyde-inactivated virus.


Fig. 1. Detection of influenza virus proteins in Western-blot analysis. Purified influenza virus proteins (0.5 μg/lane) were subjected to SDS-PAGE under reducing conditions. After blotting on a PVDF membrane, the proteins were detected by incubation with the eight monoclonal antibodies (mAbs), followed by incubation with the peroxidase-labeled F(ab')₂ fragment of donkey anti-mouse IgG. The mAbs were then visualized by chemiluminescent reaction. A, authentic anti-H5_hemagglutinin mAb; B, authentic anti-H5_neuraminidase mAb; C, authentic anti-H1_ hemagglutinin mAb; D, Niid_H5A; E, Niid_H5E; F, Niid_H5F; G, Niid_150KA. The molecular weight markers are shown on the left.

Western blot analyses with the mAbs: Five mAbs (Niid_H5A, Niid_H5B, Niid_H5C, Niid_H5D, Niid_H5E) detected the 57-kDa H5_H1 protein by Western blot analysis, which suggests that the antibodies detected the linear epitope(s) of a HA1 fragment of H5_HA (Table 1 and Fig. 1). These antibodies also detected the 60-kDa recombinant H5-HA containing the His-tag. One of these clones, Niid_H5E, detected a 40-kDa sub-fragment of recombinant HA1, which suggests that the antigenic footprint detected by the mAb differs from

that of the other four clones (Fig. 1). Niid-H5F, which reacted strongly to NIBRG-14 and rHA (H5) in ELISA, did not react to any proteins by Western blot analysis, presumably because the mAb detects a conformational epitope of H5-HA. The remaining clone, Niid_150KA, detected an unknown high molecular weight protein of approximately 150 kDa.

IFA with mAbs: Upon IFA, the HA-specific mAbs Niid-H5A and Niid_H5F, the NA-specific mAb Niid-N1A, and the Niid_150KA mAb that detects an

Fig. 2. Fluorescent immunostaining of H5N1 virus-infected MDCK cells with monoclonal antibodies (mAbs). Paraformaldehyde-fixed, H5N1 virus-infected MDCK cells were permeabilized by TBS-Tween and incubated with biotinylated mAbs. The mAbs were detected with Qdot655-conjugated streptavidin (red). Shown are representative staining patterns with Niid_H5A, Niid_H5F, Niid_N1A, and Niid_150KA. The negative control staining without mAb is shown on top. The nuclei were counterstained with DAPI (blue).

unknown 150-kDa protein bound to NIBRG-14-infected MDCK cells (Fig. 2). With the exception of Niid_H5F, these mAbs detected both the perinuclear region and the cell surface of NIBRG-14-infected MDCK cells. Niid_H5F did not detect the perinuclear region (presumably the Golgi body), which suggests that the antigenic footprint detected by this mAb differs from those of the other mAbs.

Immunohistochemistry: The Niid_H5C and Niid_H5D mAbs detected influenza virus antigens in the epithelial cells of the bronchioles and alveoli of 4% formaldehyde-fixed, paraffin-embedded lung tissue sections from mice infected with A/Vietnam/1194/2004 (NIBRG-14) (Fig. 3a). However, none of the mAbs detected influenza virus antigen in lung tissue sections from mice infected with A/HongKong/483/97 (HK483) (Fig. 3). In contrast, a polyclonal antibody against type A influenza nucleoprotein detected type A influenza virus nucleoprotein in the tissue sections from both the NIBRG-14- and HK483-infected mice (Fig. 3b, d). Thus, Niid_H5C and Niid_H5D specifically detected the HA antigen of A/Vietnam/1194/2004 (NIBRG-14). The specificity of these mAbs was then examined by using autopsied lung tissue sections from patients infected

with seasonal influenza virus (H1N1) or 2009 pandemic influenza virus (2009H1N1pdm). Niid_H5C did not exhibit any crossreactivity, but the Niid_H5D mAb did show non-specific staining with the human lung section. Two other mAbs, Niid_H5B and Niid_N1A, were also subjected to such immunohistochemical analysis but did not show any reaction.

Neutralization assay with mAbs: The ability of the mAbs to neutralize several H5N1 influenza strains was then tested (Table 2). The four purified H5N1 virus strains, NIBRG-14, Indo-RG2, NIBRG-23, and Anhui-RG5, were diluted to 2-3 $\times$ 10^2 TCID$_{50}$/0.05 mL (Table 2, lower panel) and incubated with titrated amounts of anti-H5_HA mAbs. The remaining infectivity was then noted (Table 2, upper panel). Niid_H5A most potently neutralized the NIBRG-14 strain; it completely neutralized influenza virus infectivity at a concentration of 78 ng/mL. However, Niid_H5A was less potent in neutralizing the Indo-RG2 and Anhui-RG5 strains, which indicates that the neutralizing ability of this mAb was clade-dependent. In contrast, Niid_H5F and Niid_H5D exhibited relatively broad neutralizing abilities, since they neutralized all of the strains that were tested. Niid_H5C and Niid_H5E also showed characteristic clade-

Fig. 3. Immunohistochemical analyses of lung sections from mice infected with A/Vietnam/1194/2004 (NIBRG-14) or A/HongKong/483/97 (HK483) virus. (a, b) Influenza virus antigens were detected in the epithelial cells of the bronchioles and alveoli of the mouse infected with A/Vietnam/1194/2004 (NIBRG-14) by the Niid_H5C clone (a) and polyclonal antibody against type A influenza nucleoprotein (b). (c, d) Virus antigens were not detected in the lung tissue section of the mouse infected with A/HongKong/483/97 (HK483) when Niid_H5C was used (c). However, virus antigens were detected in this section when a polyclonal antibody against type A influenza nucleoprotein was employed (d).

Table 2. Neutralizing ability of the eight mAbs generated in this study

Clone	Neutralizing antibody titer (ng/mL)			
	NIBRG-14 (clade 1)	Indo-RG2 (clade 2.1)	NIBRG-23 (clade 2.2)	Anhui-RG5 (clade 2.3)
Niid_H5A	78	>10,000	625	>10,000
Niid_H5C	625	625	313	>10,000
Niid_H5D	625	625	313	5,000
Niid_H5E	625	>10,000	>10,000	>10,000
Niid_H5F	313	313	156	2,500

Test no.	Virus infection index (Log_{10} $TCID_{50}$/0.05 mL)			
	NIBRG-14	Indo-RG2	NIBRG-23	Anhui-RG5
1	2.5	3.1	2.4	2.1
2	2.0	NT	2.0	2.4

The in vitro neutralization assay examined the ability of the mAbs to neutralize H5N1 virus infection of cultured MDCK cells. Briefly, purified H5N1 virus was diluted to 2-3 × 10^2 $TCID_{50}$/0.05 mL (the quantities are shown in the lower table) and incubated with serially-titrated purified mAbs for 1 h at 37°C. The samples were then placed into 96-well plates in which MDCK cells had been grown to 90% confluence. After 48 h, the cytotoxicity of the mAb-treated viruses was visualized by staining the cells with crystal violet. NT, not tested.

dependency, suggesting that the epitopes of these mAbs differ. Interestingly, the mAbs were least able to neutralize Anhui-RG5. This may reflect the genetic distance between Anhui-RG5 (clade 2.3) and NIBRG-14 (clade 1).

Antigen-capture ELISA: To quantitatively detect H5N1 virus, we constructed a sandwich ELISA-based virus antigen-capture detection system. Preliminary experiments tested all combinations of two mAbs from the eight mAbs; Niid_H5F had the highest detection sensitivity for purified H5N1 virion and reacted broadly to the H5_HA of viruses belonging to clades 1, 2.1, 2.2, and 2.3. Therefore, Niid_H5F was selected as the antigen-capturing mAb. The antigen-capture ELISA was constructed by immobilizing Niid_H5F (and/or Niid_ H5C) on the ELISA plate and using biotinylated Niid_ H5D as the detection mAb, since this combination gave the best results (data not shown). Since the eight mAbs

Fig. 4. ELISA reactivity of the Niid_H5A and Niid_H5F monoclonal antibodies (mAbs) to various influenza virus strains. Different influenza virus strains were immobilized on 96-well plates and incubated with biotinylated Niid_ H5A or Niid_H5F mAbs followed by peroxidase-labeled streptavidin. The binding of the mAbs was then quantitated by a colorimetric assay using TMB as a substrate.

were originally raised against the H5N1 virus strain A/Vietnam/1194/2004 (NIBRG-14), the validity of this system with other strains of H5N1 virus was also examined. As shown in Fig. 4, this system could detect the A/Indonesia/05/2005 (Indo5/PR-8-RG2), A/Turkey/1/2005 (NIBRG-23), and A/Anhui/01/2005 (Anhui01/PR8-RG5) strains but none of the non-H5N1 strains. The sandwich ELISA could detect H5N1 virus protein at concentrations as low as 50 ng/mL HA, namely, >3 SD of negative samples (Fig. 5).

DISCUSSION

In the present study, mAbs against H5N1 influenza virus were established. These mAbs could detect the virus when used in Western blot analyses, IFA, immunohistochemical analyses, neutralization assays, and antigen-capture ELISA. The characteristics of the mAbs are summarized in Table 1.

Of the eight mAb clones that reacted to H5N1 virus in ELISAs, six reacted to rHA. Only one clone reacted to NA protein. Another clone detected an unknown 150-kDa molecule upon Western blot analysis. A hybridoma that secreted a mAb that could detecte the nuclear protein or other protein components of H5N1 virus was

not detected, presumably because the first screening step identified H5 specificity. These results indicate that the HA protein is a dominant target in the antibody response of HA-subtype specificity, as suggested by other studies (17,18). There is accumulating evidence that the influenza strain-specific epitopes are often localized on the HA1 region, whereas the epitopes that are conserved among various strains are localized on the HA2 region (19–22). It has been reported that the immune response elicited by H1N1pdm yields a high frequency of HA2-specific mAbs (23,24). In the present study, none of the established clones detected the HA2 fragment of H5HA, presumably because this study focused on H5-specific clones.

The mAbs isolated in the present study were assessed for their ability to detect H5N1 virus-infected MDCK cells in IFA. Indeed, the anti-HA and anti-NA mAbs detected the cytoplasmic Golgi-rich region and the cell surface membrane. This reflects the common assembly process of influenza virus (25).

In general, a single diagnostic test is not reliable because of the potential for false positives and negatives. Considering the restricted availability of RNA detection systems (26,27), serological screening systems other than those that detect antibodies are currently being ex-

Fig. 5. Antigen-capture ELISA reactivity of monoclonal antibodies (mAbs) to H5N1 and H1N1 virus strains. The anti-H5 mAb Niid_H5F was immobilized on 96-well plates and reacted with serially-titrated purified H5N1 virus fractions for 1 h at room temperature. The bound virus proteins were detected by incubation with biotinylated Niid_H5D (anti-H5) antibody followed by peroxidase-labeled streptavidin. The binding was quantitated by a colorimetric assay that used TMB as a substrate. Abscissa, concentration of purified H5N1 virus proteins. Ordinate, absorbance unit (OD490).

amined. ELISA-based antigen-capture assays offer high specificity and reproducibility and have been used to diagnose and monitor many diseases. The present study describes the development of an antigen-capture ELISA system that detects purified H5N1 virus virion at levels as low as 50 ng/mL. The sensitivity of this system, which comprises three anti-HA mAbs, appears sufficiently high to detect virus protein in patient sera, particularly since a recently reported antigen-capture ELISA system detects 50 ng/mL of purified recombinant HA1 protein (28). At present, the sensitivity of the system is being improved, and its usefulness in diagnosing and monitoring H5N1 virus infections is being validated.

The five selected anti-HA mAbs exhibited significant neutralization activity against several viral strains in a clade-dependent manner (Table 2). Of these, Niid_H5F showed the broadest spectrum of neutralization activity, but it neutralized NIBRG-23 (clade 2.2) more efficiently than the original immunogen NIBRG-14 (clade 1). It would be of interest to determine the features that determine this clade-dependency of mAb recognition. It is also possible that these mAbs have therapeutic potential, if humanized by means of complementarity determining region grafting or mouse-human chimerism.

In conclusion, eight new H5N1-specific mAbs were generated from A/Vietnam/1194/2004 (NIBRG-14)-hyperimmunized mice, six of which were HA-specific. These mAbs were useful in Western blot analyses, IFA, and immunohistology and had in vitro neutralization activity against H5N1 viruses. These mAbs also perform well in a highly sensitive antigen-capture sandwich

ELISA system. As such, these mAbs may be useful for the rapid and specific diagnosis of H5N1 subtype influenza virus and may have therapeutic potential.

REFERENCES

1. Chan, M.C., Cheung, C.Y., Chui, W.H., et al. (2005): Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res., 6, 135.
2. World Health Organization Global Influenza Program Surveillance Network (2005): Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis., 11, 1515–1521.
3. Webster, R.G. and Govorkova, E.A. (2006): H5N1 influenza—continuing evolution and spread. N. Engl. J. Med., 355, 2174–2177.
4. Webster, R.G., Guan, Y., Peiris, M., et al. (2002): Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern china. J. Virol., 76, 118–126.
5. World Health Organization: Online at ⟨http://www.who.int/ csr/disease/avian_influenza/country/cases_table_2011_2008_ 2019/en/index.html⟩.
6. Uyeki, T.M. (2009): Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin. Infect. Dis., 49, 279–290.

7. Gambotto, A., Barratt-Boyes, S.M., de Jong, M.D., et al. (2008): Human infection with highly pathogenic H5N1 influenza virus. Lancet, 371, 1464–1475.

8. Abdel-Ghafar, A.N., Chotpitayasunondh, T., Gao, Z., et al. (2008): Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med., 358, 261–273.

9 de Jong, M.D., Simmons, C.P., Thanh, T.T., et al. (2006): Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med., 12, 1203–1207.

10. Centers for Disease Control and Prevention: Seasonal Influenza (Flu). Influenza Diagnostic Testing Algorithm. Online at 〈http: // www.cdc.gov / flu / professionals / diagnosis / testing_algorithm.htm〉.

11. Wright, P.F., Neumann, G. and Kawaoka, Y. (2007): Orthomyxoviridae. Lippincott Williams & Wilkins, Philadelphia.

12. World Health Organization: Influenza Continuing Progress towards a Unified Nomenclature System for the Highly Pathogenic H5N1 Avian Influenza Viruses. Online at 〈http://www.who.int/influenza/resources/documents/h5n1_nomenclature/en/〉.

13. Takahashi, Y., Hasegawa, H., Hara, Y., et al. (2009): Protective immunity afforded by inactivated H5N1 (nibrg-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J. Infect. Dis., 199, 1629–1637.

14. Kozbor, D. and Roder, J.C. (1984): In vitro stimulated lymphocytes as a source of human hybridomas. Eur. J. Immunol., 14, 23–27.

15. Storch, G.A. (2001): Diagnostic virology. p. 493–531. Lippincott Williams & Wilkins, Philadelphia.

16. Ohnishi, K., Sakaguchi, M., Kaji, T., et al. (2005): Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn. J. Infect. Dis., 58, 88–94.

17. Graves, P.N., Schulman, J.L., Young, J.F., et al. (1983): Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology, 126, 106–116.

18. Russ, G., Polakova, K., Kostolansky, F., et al. (1987): Monoclonal antibodies to glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. Acta Virol., 31, 374–386.

19. Kashyap, A.K., Steel, J., Oner, A.F., et al. (2008): Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. USA, 105, 5986–5991.

20. Throsby, M., van den Brink, E., Jongeneelen, M., et al. (2008): Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IGM⁻ memory B cells. PLoS One, 3, e3942.

21. Sui, J., Hwang, W.C., Perez, S., et al. (2009): Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol., 16, 265–273.

22. Ekiert, D.C., Bhabha, G., Elsliger, M.A., et al. (2009): Antibody recognition of a highly conserved influenza virus epitope. Science, 324, 246–251.

23. Corti, D., Suguitan, A.L., Jr., Pinna, D., et al. (2010): Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest., 120, 1663–1673.

24. Wrammert, J., Koutsonanos, D., Li, G.M., et al. (2011): Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med., 208, 181–193.

25. Palese, P. and Shaw, M.L. (2007): Orthomyxoviridae: the viruses and their replication. p. 1647. Lippincot Williams & Wilkins, Philadelphia.

26. Imai, M., Ninomiya, A., Minekawa, H., et al. (2007): Rapid diagnosis of H5N1 avian influenza virus infection by newly developed influenza H5 hemagglutinin gene-specific loop-mediated isothermal amplification method. J. Virol. Methods, 141, 173–180.

27. Wei, H.L., Bai, G.R., Mweene, A.S., et al. (2006): Rapid detection of avian influenza virus a and subtype H5N1 by single step multiplex reverse transcription-polymerase chain reaction. Virus Genes, 32, 261–267.

28. He, Q., Velumani, S., Du, Q., et al. (2007): Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clin. Vaccine Immunol., 14, 617–623.

Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards

Ruth Harvey[a], Michelle Hamill[b], James S. Robertson[a], Philip D. Minor[a], Galina M. Vodeiko[c], Jerry P. Weir[c], Hitoshi Takahashi[d], Yuichi Harada[d], Shigeyuki Itamura[d], Pearl Bamford[e], Tania Dalla Pozza[e], Othmar G. Engelhardt[a],*

[a] Division of Virology, National Institute for Biological Standards and Control, Health Protection Agency, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
[b] BioStatistics, National Institute for Biological Standards and Control, Health Protection Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
[c] Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Bethesda, MD 20892, USA
[d] Center for Influenza Virus Research, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama-shi, Tokyo 208 0011, Japan
[e] Therapeutic Goods Administration, PO Box 100, Woden ACT 2606, Australia

ARTICLE INFO

ABSTRACT

Each year the production of seasonal influenza vaccines requires antigen standards to be available for the potency assessment of vaccine batches. These are calibrated and assigned a value for haemagglutinin (HA) content. The calibration of an antigen standard is carried out in a collaborative study amongst a small number of national regulatory laboratories which are designated by WHO as Essential Regulatory Laboratories (ERLs) for the purposes of influenza vaccine standardisation. The calibration involves two steps: first the determination of HA protein in a primary liquid standard by measurement of total protein in a purified influenza virus preparation followed by determination of the proportion of HA as determined by PAGE analysis of the sample; and second, the calibration of the freeze-dried reference antigen against the primary standard by single radial immunodiffusion (SRD) assay. Here we describe a collaborative study to assess the effect of adding a deglycosylation step prior to the SDS-PAGE analysis for the assessment of relative HA content. We found that while the final agreed HA value of the samples tested was not significantly different with or without deglycosylation, the deglycosylation step greatly improved between-laboratory agreement.

© 2012 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Vaccination against seasonal and pandemic influenza virus remains an important strategy to reduce morbidity and mortality associated with the disease [1]. Inactivated seasonal trivalent vaccines produced by numerous manufacturers worldwide currently contain standardized amounts of the haemagglutinin (HA) from an A/H1N1, A/H3N2 and B strain of influenza virus. Due to rapid mutation in influenza viruses (antigenic drift), the World Health Organisation (WHO) makes biannual recommendations for the strains to be used in the formulation of influenza vaccine, based on worldwide surveillance and characterisation of circulating strains [2]; as a result, one or more strains in the vaccine typically needs to be updated (reviewed in [3] and [4]). The potency of each lot of vaccine produced is determined by the single radial immunodiffusion assay (SRD) which has been the WHO recommended

assay for influenza vaccine potency determination since 1979 [5,6]. The use of SRD for quantitation of HA antigen in vaccine requires a set of two reference reagents, an HA antigen standard and an anti-HA sheep antiserum, that match the vaccine strain. Thus, new reagents must be prepared each time there is a change in the WHO recommended vaccine strain.

The anti-HA sheep antiserum is raised against purified HA from the recommended strain. The HA antigen reagent is typically a preparation of inactivated whole virus donated by a vaccine manufacturer that is freeze-dried by, or on behalf of, an Essential Regulatory Laboratory (ERL). To calibrate this reagent, a primary liquid standard (PLS) is prepared by an ERL from a purified virus preparation of the recommended strain. The total protein within a PLS is determined using a standard protein quantitative assay (e.g. Lowry) whilst the proportion of HA protein within the PLS is determined from a densitometric analysis of the viral proteins separated by SDS-PAGE run under both reduced and non-reduced conditions [7]. In this assay it is the protein bands of the reduced samples that are used in the quantitation, with the non-reduced

* Corresponding author. Tel.: +44 01707 641000; fax: +44 01707 641366.
E-mail address: othmar.engelhardt@nibsc.hpa.org.uk (O.G. Engelhardt).

samples run alongside to aid in identification of the protein bands where a degree of co-migration occurs. Densitometric analysis of protein bands in the non-reduced samples is not optimal for accurate quantitation because a lot of the proteins co-migrate or are present as higher molecular weight aggregates.

The calibration of a PLS is performed in a collaborative study within WHO designated ERLs, namely the Centre for Biologics Evaluation and Research (CBER), Food and Drug Administration, USA, the National Institute for Biological Standards and Control (NIBSC), Health Protection Agency, UK, the National Institute of Infectious Diseases (NIID), Japan and the Therapeutic Goods Administration (TGA), Australia. The data from all laboratories are collated so that an HA content value in µg can be assigned to the PLS. The primary standard is then used in SRD to calibrate the freeze-dried secondary standard, which is the antigen reference material used by manufacturers as well as National Control Laboratories for the potency testing of an influenza vaccine.

Quantitation of peaks from the densitometric analysis of the SDS-PAGE of purified virus preparations is sometimes technically challenging due to various degrees of co-migration of the relevant protein bands. This phenomenon is strain-dependent and not predictable. Recently we described a modification of the SDS-PAGE method to include deglycosylation of samples before analysis [8]. Because deglycosylation shifts the mobility of the HA bands within the SDS-PAGE gels, this modification improved the reproducibility of the quantitation of the HA in our laboratory. Therefore, a collaborative study was set up among the ERLs to assess the modified method in comparison to standard in-house methods of the ERLs for the calibration of HA antigen reagent.

2. Materials and methods

2.1. Study design

A panel of purified preparations of four viruses was sent to each of the four ERLs. Each laboratory tested the samples for HA content (% HA) using their standard in-house methodology and then tested the samples following a prescribed method for the deglycosylation method. Data was returned to NIBSC, collated and statistical analysis carried out to assess the reproducibility of the alternative methods within and between laboratories. Each sample was tested by each laboratory by each method at least three times, so all data shown are the average of at least 3 individual data points.

2.2. Virus concentrates

A panel of viruses was made comprised of PR8 (H1N1), NYMC X-157 (H3N2), NYMC X-161b (H3N2) and IVR-116 (H1N1). All viruses were grown in 11 day old embryonated hens' eggs. Allantoic fluid was harvested 72 h post infection and was clarified at high speed (10 000 rpm, 30 min, 4 °C, in a Beckman SW28 rotor). Virus was pelleted by centrifugation (25 000 rpm, 90 min at 4 °C in a Beckman SW28 rotor). Virus pellets were resuspended in 1 ml PBS and loaded onto an 11 ml, 10–40% continuous sucrose gradient which was centrifuged at 35 000 rpm for 35 min at 4 °C in a Beckman SW41 rotor. The virus band was harvested, made up to an appropriate volume in PBS, pelleted by centrifugation (25 000 rpm, 90 min, 4 °C, in Beckman SW28 rotor) and the final virus pellet resuspended in PBS (10 µl per egg used).

2.3. SDS-PAGE analysis

SDS-PAGE analysis was performed in each laboratory according to standard protocols. For the gel in Fig. 1 the following method was used. One to 3 µL of virus concentrate (approximately 10 µg total


Fig. 1. SDS PAGE analysis of viruses. The four viruses included in the panel to be tested by each laboratory were analysed by SDS PAGE. Sample 1, PR8; 2, NYMC X-157; 3, NYMC X-161b; 4, IVR-116. All virus samples were reduced. Viruses were compared either deglycosylated (PNGase F +), or non deglycosylated (PNGase F -).

protein) was mixed with water to a total volume of 10 µl. Loading dye (2.5 µl) with 2% (v/v) β-mercaptoethanol as reducing agent was added to each sample. Samples were heated to 95 °C for 3 min prior to loading onto the gels. Ten percent Bis-Tris gels were used and run at 125 V for 90 min using MOPS buffer (Invitrogen) followed by staining using Colloidal Blue stain (Invitrogen). Quantitation was carried out using an Imagescanner and associated software (GE healthcare). The content of HA for each sample was calculated as follows; firstly, the total viral protein value, in arbitrary units, was calculated by summing the quantitated values for the HA1, HA2, NP and M1 bands on the gel (these were the predominant bands observed in the SDS-PAGE gels of purified virus). The HA1 and HA2 values were summed to give the total HA value. The percent HA of total protein was calculated by dividing the total HA by the total protein multiplied by 100.

2.4. Deglycosylation using PNGase F

Deglycosylation was achieved using PNGase F (New England Biolabs). Approximately 10 µg (typically 1–3 µl) of each virus concentrate was denatured according to the PNGase F manufacturer's instructions in a total reaction volume of 10 µl and samples were incubated at 37 °C overnight (approx. 16 h) with 1 µl of a 1/20 dilution of PNGase F enzyme in buffer provided by the manufacturer and 1% final concentration NP40 (provided with enzyme). Loading dye (2.5 µl) with 2% (v/v) β-mercaptoethanol as reducing agent was added to each sample. Samples were heated to 95 °C for 3 min prior to loading onto SDS-PAGE gels. Gels were run and stained as above.

2.5. Statistical analysis

Statistical analysis was performed using Minitab 15 statistical software. The analysis was performed using a general linear model with the Tukey method for pair-wise comparisons [9].

3. Results

A panel of seasonal viruses was assembled and assessed by SDS PAGE analysis with and without deglycosylation (Fig. 1). The results show that when the virus samples are run under reducing conditions with no PNGaseF treatment, there are varying degrees of co-migration between the viral protein bands. Of note, the NA protein often cannot be seen on gels, as there is not enough present to produce a visible band and, as a glycoprotein, it is diffuse without deglycosylation. When deglycosylation is used, a discrete NA band may be apparent for some viruses, but, as observed in this study,

Fig. 2. HA content of viruses. Each of the four laboratories measured HA content using their in-house method (Method A) or the prescribed deglycosylation protocol (Method B). Results shown are the average of ≥3 separate experiments for each method and each sample, except for lab 4 Method A as explained in the text. The overall average for each virus/ method is also shown (average). Error bars denote standard deviations.

this is not always the case. Running the same set of virus samples under reducing conditions after deglycosylation leads to much better separation of the viral proteins, which allows more accurate and reproducible quantitation.

We analysed %HA values with (method B) or without (method A) deglycosylation treatment of samples, based on the original in-house SDS-PAGE procedures of each laboratory. In order to compare the reproducibility of the methods among laboratories a single method for calculating the %HA content as described in materials and methods was used. One participant, laboratory 4, did not have an in-house experimental method for the quantitation of %HA and uses an assumed value of 35% instead, based on historical experience for assignment of HA content to the PLS. Therefore, no method A was included in the statistical analysis for laboratory 4, but an assumed value 35% is included in the results of the study shown in Fig. 2.

Tables 1 (method A) and 2 (method B) show individual means for each method, lab and virus calculated using data from replicate responses, expressed as %HA protein of the total viral protein in a sample. Overall means for each lab were calculated as the mean of the four individual virus means within the lab, and overall means for each virus were calculated as the mean of the individual lab means for each of the viruses.

The results for all viruses were similar for both methods, with an overall mean of 44%HA for method A and a mean of 48%HA for method B.

Within a virus, variability between labs depended on the method, with method B appearing to have better agreement

between labs than method A. This is reflected by the between lab CV for individual viruses, which ranged from 10% to 30% for method A and 5%–9% for method B. Similarly, the overall between lab variability was lower for method B than for method A (6% and 19% respectively), indicating an overall improved agreement between labs for method B as compared to method A.

Between replicate variability (Tables 3 and 4) was assessed by pooling individual CVs calculated from replicate responses within each lab and virus. Estimates were pooled both across viruses within a lab to give a pooled estimate of within lab, between replicate variation, and across labs within a virus to give a pooled estimate of within virus, between replicate variation. An overall pooled estimate of between replicate variability for each method was calculated using the average of the pooled standard deviations and the overall mean for the particular method.

Overall pooled estimates for both methods were similar (7.0% for method A and 5.8% for method B) indicating similar between replicate variability for the two methods.

For method A, pooled CVs within a lab and virus were less than 10%, with the exception of lab 3 which was marginally more variable at 13.6%. This was due to two viruses, NYMC X-161b and NYMC X-157 which had higher between replicate variability (16.1% and 18.6% respectively) than viruses PR8 and IVR-116 (3.9% and 1.3% respectively). This is reflected also by the pooled within virus CVs which are higher for NYMC X-161b and NYMC X-157 (9.1% and 9.4%) than for PR8 and IVR-116 (3.5% and 5.9%). Comparing the pooled within lab CVs and the between virus CVs (Tables 1 and 3) and taking into

Table 1
Method A lab and virus means with between-lab %CVs.

Virus	Method A			Virus mean	Between lab %CV
	Lab 1	Lab 2	Lab 3		
IVR-116	36.85	55.88	33.02	**41.92**	**29.21**
NYMC X-157	45.21	49.32	39.76	**44.76**	**10.71**
NYMC X-161b	43.10	51.07	37.56	**43.91**	**15.47**
PR8	43.57	56.00	36.96	**45.51**	**21.24**
Lab Mean	**42.18**	**53.07**	**36.83**	**44.03 (overall)**	**18.80**

Values shown are the averages of at least 3 independent experiments.
Bold indicates means between viruses and/or labs, as well as CVs.

Table 2
Method B lab and virus means with between-lab %CVs.

Virus	Method B				Virus mean	Between lab %CV
	Lab 1	Lab 2	Lab 3	Lab 4		
IVR-116	46.62	54.46	46.72	44.67	**48.12**	**9.00**
NYMC X-157	49.23	50.46	47.31	42.81	**47.45**	**7.07**
NYMC X-161b	45.87	50.67	44.37	46.09	**46.75**	**5.82**
PR8	45.73	52.16	48.44	49.19	**48.88**	**5.41**
Lab Mean	**46.86**	**51.94**	**46.71**	**45.63**	**47.79 (overall)**	**5.91**

Values shown are the averages of at least 3 independent experiments.
Bold indicates means between viruses and/or labs, as well as CVs.

Table 3
Method A pooled CVs (within lab and within virus – based on replicate tests).

Method A						
Lab			Virus			
1	2	3	IVR-116	NYMC X-157	NYMC X-161b	PR8
5.46	4.72	13.55	5.93	9.38	9.11	3.50
7.02						

Table 4
Method B Pooled CVs (within lab and within virus – based on replicate tests).

Method B							
Lab				Virus			
1	2	3	4	IVR-116	NYMC X-157	NYMC X-161b	PR8
3.53	5.84	6.10	7.90	6.14	5.71	6.32	5.54
5.75							

account the range of variability between replicates in lab 3, there is no evidence to suggest that the variability between viruses is anything more than assay variation. However, the pooled within virus CVs are much lower (3.5%–9.4%) than the between lab CVs (10%–30% from Table 1), suggesting that the variability between labs for method A is greater than assay variation alone. This was confirmed by two-way analysis of variance where all labs were significantly different from all other labs ($p < 0.001$ in all cases).

For method B, all pooled CVs were less than 10% and were comparable with the between lab and between virus figures from Table 2 indicating that the %CVs from Table 2 are similar to assay variation. However, a two-way analysis of variance showed the mean for lab 2 to be higher than all other labs; although the difference in means was small, it was statistically significant ($p < 0.001$). No significant differences were found between any other labs ($p > 0.05$ in all cases).

From the data provided, both methods A and B give similar overall mean %HA results (44%, Table 1, and 48%HA, Table 2, respectively). Overall assay variation, as measured by the overall pooled %CV's was similar for both methods. The variability between viruses was low for both methods and comparable with between replicate variability, however method B showed improved agreement between labs compared to method A.

4. Conclusion

We have previously demonstrated that a modification of the SDS-PAGE method to include deglycosylation of samples before analysis improved the reproducibility of the quantitation of the HA of H5N1 viruses in our laboratory [8]. A study by Li et al. [10] also showed that the modified method led to very reproducible data for HA content (% HA) in pandemic H1N1 viruses. Here we have demonstrated that the new protocol for determination of HA content, which involves deglycosylation of the samples prior to running SDS-PAGE, improved the agreement between the laboratories participating in the study. The study involved 4 ERL laboratories assessing the HA content for a panel of seasonal influenza viruses using their current standard in-house method and the new prescribed method for deglycosylation. The overall results for percentage HA content, while displaying a trend towards slightly higher HA content values, were not statistically significantly changed by use of the modified method, which is a reflection of the robustness of the methods currently used; however, a move towards even closer agreement between the results generated is a significant improvement. This study was carried out using a small selection of seasonal influenza A virus samples. The level of glycosylation can vary (significantly) between different

influenza viruses and so it may be found in the future that this method is even more useful for particularly problematic viruses. For example, some H5N1 strains have been shown previously [8] to have a significant problem of co-migration of proteins due to the level of glycosylation of the HA. It may be of value to continue the comparison of currently used methods alongside the deglycosylation protocol during the calibration of reference reagents over a number of influenza seasons to obtain more data and to fully assess the suitability of such a method for the calibration of reagents in the future. The deglycosylation step may need to be optimised for each new strain at the start of a season as we have seen some differences between viruses in the sensitivity to the PNGase F enzyme, with some viruses requiring longer periods of treatment, or more enzyme in the reaction (data not shown). In the future we can also investigate ways to improve agreement for the total protein determination, which is the other part of the collaborative process for calibration of potency reference reagents. There is potential to optimise this part of the assay as well as the HA quantitation procedure and so improve the reproducibility of calibration further. In the future it might be worth investigating the standardisation of SDS-PAGE gel consumables, equipment and protocols as well as standardisation of the quantitation procedure between the ERLs; however, as the present study shows, this is not needed urgently. Other physicochemical methods such as mass spectrometry can also be used to measure the absolute amount of a protein in a sample; ultimately a method such as this may be even more accurate. However, a lot of assay development and validation would be required before a new method like that could be employed, and a method like mass spectrometry requires more expertise and specific equipment, so it may be some time before it could be used routinely in all ERLs. Overall this study shows that the new method is more reproducible and thus has the potential to improve the calibration of influenza reference antigen reagents.

References

[1] Germann TC, Kadau K, Longini IM, Macken CA. Mitigation strategies for pandemic influenza in the United States. PNAS 2006;103:5935–40.
[2] Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008;26S:D31–4.
[3] Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010;85(3):257–73.
[4] Orenstein WA, Schaffner W. Lessons Learned: Role of influenza vaccine production, distribution, supply and demand – What it means for the provider. Am J Med 2008;121:S22–7.
[5] Wood JM, Schild GC, Newman RM, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for the potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977;5:237–47.
[6] WHO. WHO Expert committee on Biological Standardization. Thirteenth report. Geneva: World Health Organisation; 1979. Annex 3 (WHO Technical Report Series, No. 638).
[7] Wood JM, Mumford JA, Dunleavy U, Seagroatt V, Newman RW, Thornton D, et al. Single radial immunodiffusion potency tests for inactivated equine influenza vaccines. In: Powell DG, editor. Equine infection disease V. Proc. Fifth International Conference. Kentucky: The University Press; 1988. p. 74–9.
[8] Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008;26:6550–4.
[9] Hsu JC. Multiple comparisons, Theory and methods. Chapman and Hall; 1996.
[10] Li C, Shao M, Cui X, Song Y, Li J, Yuan L, et al. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals 2010;38:284–9.